Management of systemic sclerosis-associated interstitial lung disease in the current era.
作者信息
Amjadi Sogol Sara, Roofeh David, Namas Rajaie, Khanna Dinesh
机构信息
Dignity Health, Henderson, NV, USA.
Scleroderma Program, University of Michigan, Ann Arbor, MI, USA.
出版信息
Int J Rheum Dis. 2020 Feb;23(2):137-139. doi: 10.1111/1756-185X.13799.
Abstract
摘要
相似文献
1
Management of systemic sclerosis-associated interstitial lung disease in the current era.当代系统性硬化症相关间质性肺疾病的管理
Int J Rheum Dis. 2020 Feb;23(2):137-139. doi: 10.1111/1756-185X.13799.
2
Interstitial lung disease points to consider for clinical trials in systemic sclerosis.系统性硬化症临床试验中需考虑的间质性肺疾病要点。
Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v27-v32. doi: 10.1093/rheumatology/kex203.
3
[MANAGEMENT OF CONNECTIVE TISSUE DISEASE-ASSOCIATED INTERSTITIAL LUNG DISEASE].[结缔组织病相关间质性肺病的管理]
Arerugi. 2017;66(9):1161-1164. doi: 10.15036/arerugi.66.1161.
4
Interstitial lung disease in scleroderma.硬皮病中的间质性肺疾病
Rheum Dis Clin North Am. 2015 May;41(2):237-48. doi: 10.1016/j.rdc.2014.12.005. Epub 2015 Feb 26.
5
Are serum biomarkers useful in the management of systemic sclerosis-associated interstitial lung disease?
Respirology. 2021 May;26(5):406-408. doi: 10.1111/resp.14017. Epub 2021 Feb 20.
6
Recent progress in systemic sclerosis-interstitial lung disease.系统性硬皮病-间质性肺病的最新进展。
Curr Opin Rheumatol. 2018 Nov;30(6):570-575. doi: 10.1097/BOR.0000000000000544.
7
Recent advances in the diagnosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma): a review.系统性硬化症（硬皮病）间质性肺疾病的诊断和治疗新进展：综述。
Clin Exp Rheumatol. 2011 Mar-Apr;29(2 Suppl 65):S66-74. Epub 2011 May 13.
8
Clinical Trial Enrichment in Systemic Sclerosis-Associated Interstitial Lung Disease: The Search Continues.
Chest. 2023 Mar;163(3):475-476. doi: 10.1016/j.chest.2022.11.001.
9
[Interstitial pulmonary disease in systemic scleroderma: treatment].[系统性硬化症中的间质性肺疾病：治疗]
Dtsch Med Wochenschr. 2002 Mar 8;127(10):520-2. doi: 10.1055/s-2002-20928.
10
Comment on 'Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?'.
Autoimmun Rev. 2016 Feb;15(2):202. doi: 10.1016/j.autrev.2015.06.007. Epub 2015 Jun 26.
引用本文的文献
1
[Characteristics of patients with systemic sclerosis who develop interstitial lung disease].[发生间质性肺疾病的系统性硬化症患者的特征]
Rev Med Inst Mex Seguro Soc. 2023 Oct 2;61(Suppl 3):S363-S371. doi: 10.5281/zenodo.8383951.
2
Exome sequencing link mutation in with systemic sclerosis-associated interstitial lung disease and the low level of testosterone-an exploration study.外显子组测序揭示与系统性硬化症相关间质性肺病及低睾酮水平相关的突变——一项探索性研究
Front Oncol. 2022 Sep 8;12:956552. doi: 10.3389/fonc.2022.956552. eCollection 2022.
3
Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process.用于系统性硬化症相关间质性肺病肺生理学的结局测量工具选择：使用 OMERACT 过滤器 2.1 过程的系统评价。
Semin Arthritis Rheum. 2021 Dec;51(6):1331-1341. doi: 10.1016/j.semarthrit.2021.08.001. Epub 2021 Aug 20.
4
Hospitalisations related to systemic sclerosis and the impact of interstitial lung disease. Analysis of patients hospitalised at the University of Michigan, USA.与系统性硬化症相关的住院治疗以及间质性肺疾病的影响。对在美国密歇根大学住院的患者进行分析。
Clin Exp Rheumatol. 2021 Jul-Aug;39 Suppl 131(4):43-51. doi: 10.55563/clinexprheumatol/9ivp9g. Epub 2021 Mar 10.
本文引用的文献
1
Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.系统性硬化症伴间质性肺病的病因、危险因素和生物标志物。
Am J Respir Crit Care Med. 2020 Mar 15;201(6):650-660. doi: 10.1164/rccm.201903-0563CI.
2
Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort.追踪系统性硬化症中肺间质疾病的影响：一项全国性完整队列研究。
Am J Respir Crit Care Med. 2019 Nov 15;200(10):1258-1266. doi: 10.1164/rccm.201903-0486OC.
3
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.尼达尼布治疗系统性硬化症相关间质性肺疾病。
N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076. Epub 2019 May 20.
4
Management of systemic sclerosis-associated interstitial lung disease.系统性硬皮病相关间质性肺疾病的管理。
Curr Opin Rheumatol. 2019 May;31(3):241-249. doi: 10.1097/BOR.0000000000000592.
5
Diagnosis of pulmonary hypertension.肺动脉高压的诊断。
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01904-2018. Print 2019 Jan.
6
Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.系统性硬化症患者的间质性肺病短期进展可预测两个独立临床试验队列的长期生存。
Ann Rheum Dis. 2019 Jan;78(1):122-130. doi: 10.1136/annrheumdis-2018-213708. Epub 2018 Nov 8.
7
Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial.静脉注射环磷酰胺与利妥昔单抗治疗早期弥漫性硬皮病肺疾病：开放标签、随机、对照试验。
Rheumatology (Oxford). 2018 Dec 1;57(12):2106-2113. doi: 10.1093/rheumatology/key213.
8
Haematopoietic stem cell transplantation in systemic sclerosis.系统性硬化症中的造血干细胞移植
RMD Open. 2018 Jun 17;4(1):e000533. doi: 10.1136/rmdopen-2017-000533. eCollection 2018.
9
Screening High-Resolution Computed Tomography of the Chest to Detect Interstitial Lung Disease in Systemic Sclerosis: A Global Survey of Rheumatologists.胸部高分辨率计算机断层扫描筛查系统性硬化症中的间质性肺疾病：风湿病学家的全球调查
Arthritis Rheumatol. 2018 Jun;70(6):971-972. doi: 10.1002/art.40441. Epub 2018 Apr 24.
10
Evaluation and management approaches for scleroderma lung disease.硬皮病肺病的评估与管理方法
Ther Adv Respir Dis. 2017 Aug;11(8):327-340. doi: 10.1177/1753465817713680. Epub 2017 Jun 16.
Zotero 插件